Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study

Guo-Li Sun, Li Lei, Liwei Liu, Jin Liu, Yibo He, Zhaodong Guo, Xiaohua Dai, Lihao He, Shi-Qun Chen, Yan Liang, Jianfeng Ye, Yunzhao Hu, Guoqin Chen, Ji-Yan Chen, Yong Liu, Guo-Li Sun, Li Lei, Liwei Liu, Jin Liu, Yibo He, Zhaodong Guo, Xiaohua Dai, Lihao He, Shi-Qun Chen, Yan Liang, Jianfeng Ye, Yunzhao Hu, Guoqin Chen, Ji-Yan Chen, Yong Liu

Abstract

Background: Dual antiplatelet therapy (DAPT) is frequently discontinued after drug-eluting stent (DES) implantation, which could increase the risk of major adverse cardiovascular events (MACEs). Few studies have attempted to improve DAPT adherence through web-based social media.

Objective: To explore the effect of social media on DAPT adherence following DES implantation.

Methods/design: The WeChat trial is a multicentre, single-blind, randomised study (1:1). It will recruit 760 patients with DES who require 12 months of DAPT. The control group will only receive usual care and general educational messages on medical knowledge. The intervention group will receive a personalised intervention, including interactive responses and medication and follow-up reminders beyond the general educational messages. The primary endpoint will be the discontinuation rate which is defined as the cessation of any dual antiplatelet drug owing to the participants' discretion within 1 year of DES implantation. The secondary endpoints will include medication adherence and MACEs. Both groups will receive messages or reminders four times a week with follow-ups over 12 months.

Ethics and dissemination: Ethical approval was granted by Ethics Committee of Guangdong Provincial People's Hospital (GDREC2018327H). Results will be disseminated via peer-reviewed publications and presentations at international conferences.

Trial registration number: NCT03732066.

Keywords: discontinuation rate; dual antiplatelet therapy; mobile health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flow chart of study design. DAPT, dual antiplatelet therapy; DES, drug-eluting stent.

References

    1. Lin JS, Evans CV, Johnson E, et al. . Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US preventive services Task force. JAMA 2018;320:281–97. 10.1001/jama.2018.4242
    1. Mozaffarian D, Benjamin EJ, Go AS, et al. . Heart disease and stroke Statistics-2016 update: a report from the American heart association. Circulation 2016;133:e38–60. 10.1161/CIR.0000000000000350
    1. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. . 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87–165. 10.1093/eurheartj/ehy394
    1. Ferrières J, Lautsch D, Ambegaonkar BM, et al. . Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. Int J Cardiol 2018;270:21–7. 10.1016/j.ijcard.2018.06.008
    1. Kedhi E, Fabris E, van der Ent M, et al. . Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363 10.1136/bmj.k3793
    1. Mehran R, Baber U, Steg PG, et al. . Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (Paris): 2 year results from a prospective observational study. The Lancet 2013;382:1714–22. 10.1016/S0140-6736(13)61720-1
    1. Cutlip DE, Kereiakes DJ, Mauri L, et al. . Thrombotic Complications Associated With Early and Late Nonadherence to Dual Antiplatelet Therapy. JACC: Cardiovascular Interventions 2015;8:404–10. 10.1016/j.jcin.2014.10.017
    1. Irvin MR, Shimbo D, Mann DM, et al. . Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens 2012;14:694–700. 10.1111/j.1751-7176.2012.00690.x
    1. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177–86. 10.1001/jama.297.2.177
    1. Patel R, Chang T, Greysen SR, et al. . Social media use in chronic disease: a systematic review and novel taxonomy. Am J Med 2015;128:1335–50. 10.1016/j.amjmed.2015.06.015
    1. Redfern J, Ingles J, Neubeck L, et al. . Tweeting our way to cardiovascular health. J Am Coll Cardiol 2013;61:1657–8. 10.1016/j.jacc.2013.01.041
    1. Chow CK, Redfern J, Hillis GS, et al. . Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease. JAMA 2015;314:1255–63. 10.1001/jama.2015.10945
    1. Widmer RJ, Allison TG, Lerman LO, et al. . Digital health intervention as an adjunct to cardiac rehabilitation reduces cardiovascular risk factors and rehospitalizations. J Cardiovasc Transl Res 2015;8:283–92. 10.1007/s12265-015-9629-1
    1. Nolan RP, Liu S, Feldman R, et al. . Reducing risk with e-based support for adherence to lifestyle change in hypertension (reach): protocol for a multicentred randomised controlled trial. BMJ Open 2013;3:e003547 10.1136/bmjopen-2013-003547
    1. Costa F, Van Klaveren D, Feres F, et al. . Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol 2019;73:741–54. 10.1016/j.jacc.2018.11.048
    1. Valgimigli M, Bueno H, Byrne RA, et al. . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of cardiology (ESC) and of the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J 2018;39:213–60. 10.1093/eurheartj/ehx419
    1. Cutlip DE, Kereiakes DJ, Mauri L, et al. . Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 2015;8:404–10. 10.1016/j.jcin.2014.10.017
    1. Cho MH, Shin DW, Yun JM, et al. . Prevalence and predictors of early discontinuation of Dual-Antiplatelet therapy after drug-eluting stent implantation in Korean population. Am J Cardiol 2016;118:1448–54. 10.1016/j.amjcard.2016.07.073
    1. Tian M, Ajay VS, Dunzhu D, et al. . A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard trial) in rural Tibet, China, and Haryana, India. Circulation 2015;132:815–24. 10.1161/CIRCULATIONAHA.115.015373
    1. Vinogradova Y, Coupland C, Brindle P, et al. . Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database. BMJ 2016;353 10.1136/bmj.i3305
    1. Santo K, Hyun K, de Keizer L, et al. . The effects of a lifestyle-focused text-messaging intervention on adherence to dietary guideline recommendations in patients with coronary heart disease: an analysis of the text me study. Int J Behav Nutr Phys Act 2018;15 10.1186/s12966-018-0677-1
    1. Dorje T, Zhao G, Scheer A, et al. . Smartphone and social media-based cardiac rehabilitation and secondary prevention (SMART-CR/SP) for patients with coronary heart disease in China: a randomised controlled trial protocol. BMJ Open 2018;8:e021908 10.1136/bmjopen-2018-021908
    1. Neubeck L, Lowres N, Benjamin EJ, et al. . The mobile revolution—using smartphone apps to prevent cardiovascular disease. Nat Rev Cardiol 2015;12:350–60. 10.1038/nrcardio.2015.34

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere